AustraliaHealth

Telix Pharmaceuticals (ASX:TLX) completed patient enrolment for its international, multicentre Phase 1 IPAX-2 clinical trial.

Alcidion Group (ASX:ALC) signed an asset sale agreement to acquire the business and assets of the 'Kyra flow products' from Telstra Health.

Racura Oncology (ASX:RAC) announced a milestone in its Phase 1 CPACS clinical trial, receiving formal clearance to escalate the dosage of its lead candidate, RC220.

AVITA Medical (ASX:AVH) reported its financial performance for the first quarter of 2026, headlined by a total revenue of US$19.3 million.

Pacific Edge (ASX:PEB) secured a regulatory win as Novitas publishes draft Medicare coverage for Cxbladder Triage tests.

Argenica Therapeutics (ASX:AGN) has formed a Clinical Advisory Committee to lead its Phase 2b trial for the neuroprotective candidate, ARG-007.

Nexalis Therapeutics (ASX:NX1) announced a clinical milestone following the final dosing of its Phase 1 study for IRX-616a.

Neurizon Therapeutics (ASX:NUZ) secures ethics approval for a Phase 1 study of its NUZ-001 oral liquid formulation.

Firebrick Pharma (ASX:FRE) has achieved a regulatory milestone in North America with the Canadian Intellectual Property Office.

Nexsen (ASX:NXN) has achieved a milestone in its international expansion, announcing a binding term sheet with GHK Hospital.

Cancer diagnostics firm Pacific Edge (ASX:PEB) has capitalised on investor appetite, announcing an upsized NZ$25.4 million equity placement.

Healius (ASX:HLS) narrowed its EBITDA guidance to $259M–$264M and launched a strategic asset review for FY26.